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Background:  A multicenter experience documenting the safety and efficacy of endomyocardial biopsy (EMB) in heart transplant recipients has not 
been reported.
Methods:  Cross-sectional safety data from the Congenital Cardiac Catheterization Outcomes Project database from all EMB procedures performed 
in heart transplant recipients was recorded at 8 centers from 2/1/2007 - 2/28/2010 and analyzed retrospectively. All adverse events (AE) were 
classified by two cardiologists according to a 5 level severity scale. The safety outcome was defined by the presence of a high severity AE (HSAE) 
(Level 3, 4, 5). Data on technical sufficiency of biopsy samples was collected and analyzed prospectively from 4/1/09 - 2/28/10. Rates of AE, 
technical success, and predictors in multivariate analysis are reported.
Results:  2665 EMB cases were performed in 744 heart transplant recipients, median age of 12 years [4.8-16.7] and 58% male. AE occurred in 88 
cases (3.3%), of which 28 (1.1%) were HSAE. AE attributable to EMB included 3 cases of tricuspid valve injury, 2 cases of transient heart block, and 
3 cases of transient RBBB. Among 822 cases involving coronary angiography, 10 (1.2%) resulted in a coronary related AE (1 dissection, 3 air emboli, 
4 vasospasm/ST changes, 2 arrhythmias). There were no myocardial perforations and no deaths in the entire cohort. Risk factors for HSAE included 
fewer prior catheterizations (OR 0.92 per additional procedure; p=0.007), longer case times (OR 1.14 per 10 additional minutes; p=0.003), LSCV or 
non-traditional access (OR 10.7; p<0.001), and arterial access (OR 2.9; p=0.03). EMB yielded tissue sufficient for diagnosis in 1123 of 1138 cases 
(99%). Risk factors for an insufficient EMB sample were lower cardiac index (CI) (OR 1.1 per 0.1 L/min/m2 decrease in CI; p=0.01) and more biopsy 
attempts (OR 1.2 per attempt; p<0.001).
Conclusion: In the current era, EMB can be performed in pediatric heart transplant recipients with a low AE rate. Risk of clinically important events 
is increased in early post-transplant biopsies, with longer case times, and with arterial access. EMB provides diagnostic tissue in nearly all cases. 
Lower CI and more biopsy attempts are associated with inadequate EMB sample.
